+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Pancreatic Cancer: Disease and Pipeline Analysis

  • ID: 2739710
  • Report
  • April 2013
  • 67 Pages
  • Industry Standard Research (ISR)
1 of 4
The pancreas is the 10th most common site of new cancers but is the 4th leading cause of cancer death, largely due the difficulties associated with diagnosing the disease in its early stages. As a consequence, over 80% of patients present with regional spread or distant disease at the time of diagnosis (Stage III or Stage IV) and are unsuitable for surgical resection. Survival rates from the disease are among the lowest for any type of cancer with a median survival time of 4-6 months from diagnosis, a 1-year survival rate of 26% and a 5-year survival rate of only 6%. Following curative resection, median survival time increases to between 12 and 19 months.

In a market with few available therapies that exhibit limited effectiveness and a disease class still classified as “rare”, poor survival rates and lack of viable treatment options remain compelling reasons to develop new “Orphan” therapies to address this large unmet need.
Note: Product cover images may vary from those shown
2 of 4
Table of Contents

Copyright and Usage Guidelines
Table of Abbreviations
Table of Definitions

Chapter 1. Pancreatic Cancer Overview

Chapter 2. Commercial Rationale
High Unmet Need and Limited Available Therapies
Increasing Pancreatic Cancer Incidence
Orphan Disease Status
Active Drug Development Field

Chapter 3. Environmental Analysis
Disease Epidemiology
Major Markets Environmental Analysis
Emerging Markets Environmental Analysis (BRICK)
Additional Countries

Chapter 4. Clinical Development Pipeline
R&D Trends in the Treatment of Pancreatic Cancer
Late Phase Pancreatic Cancer Development Pipeline
Masitinib, AB Science
GV-1001, KAEL-GemVax
Abraxane, Celgene Corporation
HyperAcute Pancreas, NewLink Genetics
MM-398, Merrimack Pharma
Polyclonal Antibody Stimulator, Cancer Advances Inc
Estybon (rigositib), OncoNova Therapeutics
TH302, Merck KGaA and Threshold Pharma
Early Phase Pancreatic Cancer Development Pipeline
Recent Clinical Development Failures

Chapter 5. Clinical Trial Environment
Geographic summary
About ISR

List of Tables

Table 1.Major Pancreatic Cancer Drug Treatments
Table 2.Pancreatic Cancer - Major Markets Patient Population and Product Environment
Table 3.Developed Markets Forecast Future Pancreatic Cancer Incidence
Table 4.Pancreatic Cancer - Emerging Markets Patient Population and Product Environment
Table 5.Emerging Markets Forecast Future Pancreatic Cancer Incidence
Table 6.The Late Phase Pancreatic Cancer Pipeline
Table 7.Overview of Masitinib
Table 8.Overview of GV-1001
Table 9.Overview of Abraxane
Table 10.Overview of HyperAcute Pancreas
Table 11.Overview of MM-398
Table 12.Overview of Polyclonal Antibody Stimulator
Table 13.Overview of Rigosirtib
Table 14.Overview of TH302
Table 15.Early Phase Pancreatic Cancer Development Pipeline: Immunotherapy
Table 16.Early Phase Pancreatic Cancer Pipeline: Signaling Pathway Inhibitors
Table 17.Early Phase Pancreatic Cancer Pipeline: Tumour Microenvironment
Table 18.Early Phase Pancreatic Cancer Pipeline: Chemotherapeutic Agents
Table 19.Pancreatic Cancer Trials by Development Phase: All Sponsors
Table 20.Ongoing, Industry-Sponsored Pancreatic Cancer Trials
Table 21.Recently Completed, Industry-Sponsored Pancreatic Cancer Trials

List of Figures

Figure 1.Global Map of Percentage of Tobacco Use Among Adults (2005)
Figure 2.Global Map of per Capita Adult Alcohol Consumption (Pure Alcohol, litres)
Figure 3.Countries with the Highest Populations of Pancreatic Cancer Patients
Figure 4.Countries with Highest Age Standardized Rate of Pancreatic Cancer
Figure 5.Schematic of the Major Intracellular Signaling Pathways and Drugs which Act on Them
Note: Product cover images may vary from those shown
3 of 4
This report provides insight into a market with few effective therapies.

“ISR’s latest report profiles the pancreatic cancer market because it is one in which few effective therapies are currently available and has a healthy clinical development pipeline,” explained Andrew Schafer, President of ISR. “The market data in this report is valuable for pharmaceutical and biopharmaceutical executives looking to optimize and benchmark their clinical development programs and better guide their commercial strategies by understanding the current and future competitive landscape.”

The report provides a thorough overview of the disease, provides incidence figures for all major and emerging markets, profiles the clinical development status of over 60 potential new therapies, and discusses market specific drug “approval dynamics,” such as localized trial and recruitment environments, regulatory environments, competitive product landscape, and pricing and reimbursement environments.

“Pancreatic cancer affects a relatively small number of people around the world, which in most markets classify it as an ‘orphan’ or rare disease,” Schafer explained. “This classification means favorable market conditions for pharmaceutical and biopharmaceutical sponsors willing to invest in new therapies in the form of tax breaks and market exclusivity upon regulatory approval.”

The report is based on data compiled by ISR analysts in the first quarter of 2013.
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown